14th ICID - Poster Abstracts - International Society for Infectious ...

More documents

Recommendations

Info

When citing these abstracts please use the following reference: Author(s) of abstract. Title of abstract [abstract]. Int J Infect Dis 2010;14S1: Abstract number. Please note that the official publication of the International Journal of Infectious Diseases 2010, Volume 14, Supplement 1 is available electronically on http://www.sciencedirect.com Final Abstract Number: 84.046 Session: Virology and Viral Infections (Non-HIV) Date: Friday, March 12, 2010 Time: 12:30-13:30 Room: Poster & Exhibition Area/Ground Level Type: Poster Presentation Spatial and temporal trends of the Lassa fever epidemic in Nigeria 2001 – 2009, with particular reference to the Edo State experience G. Akpede 1 , D. Asogun 1 , P. Okokhere 1 , S. Okogbenin 1 , H. Akpan H. 2 , J. Ehiemuan 1 , C. Happi 3 , S. Gunther 4 1 Irrua Specialist Teaching Hospital, Irrua, Edo, Nigeria, 2 Federal Ministry of Health, Abuja, Nigeria, 3 UCH Ibadan, Ibadan, Nigeria, 4 Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, Germany Background: The initial interest following the report of the Lassa fever (LF) epidemic in Nigeria in 1969 waned considerably unlike in the Mano River Basin countries of Sierra Leone, Liberia and Guinea. The NLFSFN was formed in 2007 to meet the need for a structured and sustained response to the control of the epidemic in Nigeria. We describe the spread of the epidemic from 2001-2007, the change in its seasonality, the rise in prevalence and the decline in case fatality rate (CFR) among hospital patients. Methods: Review of surveillance data at the Federal Ministry of Health and the Institute of Lassa Fever Research and Control, ISTH, Irrua and review of the case load and outcome of suspected LF at the ISTH. The diagnosis of LF was based on defined criteria. Results: From 2001 – 2006, 1-3 (average 1.7 or 5%) of the 36 States and the Federal Capital Territory reported LF compared to 7-12 (average 9.7) States in 2007-2009 (OR (95% CI) = 0.26 (0.13, 0.53), p
When citing these abstracts please use the following reference: Author(s) of abstract. Title of abstract [abstract]. Int J Infect Dis 2010;14S1: Abstract number. Please note that the official publication of the International Journal of Infectious Diseases 2010, Volume 14, Supplement 1 is available electronically on http://www.sciencedirect.com Final Abstract Number: 84.047 Session: Virology and Viral Infections (Non-HIV) Date: Friday, March 12, 2010 Time: 12:30-13:30 Room: Poster & Exhibition Area/Ground Level Type: Poster Presentation Immunocompromised patients with shingles - Therapeutic approach L. Zabaznoska 1 , L. Ilieva 1 , V. Markovski 1 , V. Semenakova-Cvetkovska 2 1 University Hospital of Infectious Diseases, Skopje, Macedonia, 2 Clinic for Infectious Diseases, Skopje, Macedonia Background: The complexity of the therapeutic approach of the immunocompromised patients is determinate by the capacity of their immunoresponse corresponding with the arising infection. Among the patients with shingles with a comorbide immunodeficiency syndrome such as primary hypogamaglobulinaemia or secondary lymphopenia as a result of a long lasting immunosuppressive therapeutic treatment that is even more complex, due to threatening viral generalization, including visceral generalization of the illness as well as dermal and pulmonary bacterial superinfection. Methods: During the 6 year long period, 20 immunocompromised patients with shingles were hospitalized and healed in our department. Dermal eruptions were spreaded on several dermatoms, in 8 patients with dermal generalization. Visceral generalization appeared in 4 cases with all consecutive disorders. Diagnostic criteria, including complete blood count (CBC), sedimentation, chemistry profile of renal and liver function tests, bacteriological (inducted expectorated) sputum sample testing, blood culture, pleural fluid analysis, chest x-ray and tomography, were determining moments in the diagnostic procedure and therapeutic treatment. Results: Appearance of the Acyclovir (for oral or i.v. application), as a systemic virostatic with high efficiency, dramatically changed the evolution of the illness in this group of patients, their clinical symptomatology and expression, with the drastic reduction of the sequels and the epilogue of the illness. Due to the effect of viral replication blocking, its efficiency is evident, especially if it is applicated within the first 3 days of the illness (24-48-72 hours after the appearance of the first symptoms) at the period of the most intense viral replication. These patients were parenterally/peroral treated with Acyclovir (Virolex) and antibiotics - Penicillines, II and III generation Cephalosporines, Aminoglycosides, Macrolides, Quinolones, Clindamycin, Lincomycin, Co-trimoxazol. Conclusion: All patients showed satisfying resolve of the dermal lesions, resolution of the pulmonary inflammation and correction of the chemistry profile of renal and liver function as well as abrogation of all clinical symptoms and subjective difficulties. Is it necessary to point out the importance of the substitutional and symptomatic therapy that have to be implemented simultaneously with antiviral and antibiotic therapy, as the only possible and satisfactory way of treatment of this group of patients along with necessary attention and care.
Page 1 and 2:
When citing these abstracts please
Page 3 and 4:
Page 5 and 6:
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
Page 195 and 196:
Page 197 and 198:
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
Page 205 and 206:
Page 207 and 208:
Page 209 and 210:
Page 211 and 212:
Page 213 and 214:
Page 215 and 216:
Page 217 and 218:
Page 219 and 220:
Page 221 and 222:
Page 223 and 224:
Page 225 and 226:
Page 227 and 228:
Page 229 and 230:
Page 231 and 232:
Page 233 and 234:
Page 235 and 236:
Page 237 and 238:
Page 239 and 240:
Page 241 and 242:
Page 243 and 244:
Page 245 and 246:
Page 247 and 248:
Page 249 and 250:
Page 251 and 252:
Page 253 and 254:
Page 255 and 256:
Page 257 and 258:
Page 259 and 260:
Page 261 and 262:
Page 263 and 264: When citing these abstracts please
Page 313: When citing these abstracts please
show all

14th ICID - Poster Abstracts - International Society for Infectious ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?